Boston Scientific Corp (BSX) Stock Analysis
Verdict: HOLD
Severe valuation discount following cyberattack guidance cuts is offset by strong CEO insider buying and solid 71.2% gross margins.
Investment score: 62/100
Analysis as of
Is Boston Scientific Corp stock worth reviewing? AI model thesis
The model perspectives BSX as a quality medtech leader undergoing a temporary operational reset. Strong CEO insider buying ($10M) and high 71.2% gross margins mitigate risk, but near-term guidance cuts justify a Hold stance until Q3/Q4 earnings demonstrate complete operational recovery.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Boston Scientific Corp opportunities and risks
What speaks for BSX
- Compelling Relative Valuation Discount
What speaks against BSX
- Cyberattack Disruption and Guidance Withdrawal
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BSX | 17.5x | 3.1x | 13.2x | 71.2% | 17.5% | 5.6% |
| ABT | 32.9x | 3.8x | 18.1x | 56.8% | 11.6% | 4.9% |
| ISRG | 47.6x | 13.5x | 32.2x | 66.7% | 28.4% | 2.2% |
| SYK | 29.0x | 4.2x | 17.9x | 65.2% | 14.4% | 4.3% |
| BDX | 56.4x | 2.5x | 15.2x | 46.1% | 4.5% | 5.1% |
| EW | 49.2x | 7.6x | 29.8x | 78.0% | 15.4% | 2.9% |
| Peer median | 47.6x | 4.2x | 18.1x | 65.2% | 14.4% | 4.3% |
Frequently asked questions about Boston Scientific Corp (BSX)
Is BSX stock a good investment?
The cached TradeMates AI model rates Boston Scientific Corp as HOLD with an investment score of 62/100. The model perspectives BSX as a quality medtech leader undergoing a temporary operational reset. Strong CEO insider buying ($10M) and high 71.2% gross margins mitigate risk, but near-term guidance cuts justify a Hold stance until Q3/Q4 earnings demonstrate complete operational recovery. This is algorithmic model output, not personal investment advice.
Is BSX stock a buy?
The TradeMates model verdict for BSX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.